Table 4 Risk factors associated with development of breakthrough BSI during tigecycline therapy.

From: Clinical and microbiological analysis of risk factors for breakthrough bloodstream infection during Tigecycline Therapy

Variable

Univariate analysis

Multivariable analysis1

Odds ratio (95% CI)

P value

Odds ratio (95% CI)

P value

Liver cirrhosis

4.51 (1.96–10.37)

 < 0.001

3.09 (1.13–8.46)

0.028

Solid organ transplantation

2.94 (1.30–6.68)

0.01

  

Charlson comorbidity score

1.13 (1.01–1.27)

0.043

  

Indwelling catheter2

2.76 (1.29–5.90)

0.009

3.42 (1.38–8.48)

0.008

Previous Candida colonization

7.39 (2.12–25.73)

0.002

14.95 (3.58–62.49)

 < 0.001

Previous multidrug-resistant pathogen colonization3

9.85 (5.27–18.40)

 < 0.001

10.30 (5.20–20.43)

 < 0.001

APACHE II score

1.08 (1.04–1.12)

 < 0.001

  
  1. 1The model fitted the data well in terms of discrimination (C-statistic, 0.84) and calibration (Homer-Lemeshow goodness of fit statistic, 1.46; P = 0.69).
  2. 2Indwelling catheter includes central venous catheter and percutaneous drainage.
  3. 3Multidrug-resistant isolate was defined as vancomycin-resistant Enterococcus, carbapenem-resistant Enterobacterales, carbapenem-resistant P. aeruginosa, or carbapenem-resistant A. baumannii.